Successful Treatment of Conjunctival Lymphangiectasia With Subconjunctival Injection of Bevacizumab.
To report a novel intervention for the treatment of conjunctival lymphangiectasia-subconjunctival injection of bevacizumab. A 53-year-old white male presented with a 3-month history of right ocular discomfort and redness unresponsive to conventional topical treatment of lubricants and steroids. A clinical diagnosis of conjunctival lymphangiectasia was confirmed by biopsy. Bevacizumab (25 mg/mL) was injected subconjunctivally into the affected area. An improvement in the degree of conjunctival chemosis was evident at 5 days postinjection. At 1-month follow-up, symptoms had fully resolved. No recurrence had been observed at 3 years' follow-up. Subconjunctival bevacizumab injection may be an effective treatment for conjunctival lymphangiectasia.